Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population

Rheumatology International

Volumn 32, Issue 6, 2012, Pages 1663-1667

  Lian, Fan ^a   Yang, Xiuyan ^a   Liang, Liuqin ^a   Xu, Hanshi ^a   Zhan, Zhongping ^a   Qiu, Qian ^a   Ye, Yujin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Ankylosing spondylitis; Etanercept; Hip; Methotrexate

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HLA B27 ANTIGEN; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHINESE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL ASSESSMENT; HARRIS HIP SCORE; HIP DISEASE; HIP RADIOGRAPHY; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIP JOINT; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863877431     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1844-8     Document Type: Article

References (28)

1. Brophy S, Mackay K, Al-Saidi A, Taylor G, Calin A (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29:1236-1243
2. Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319-334
3. Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 27:613-622
4. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49:483-487
5. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353-358
6. BoonenA, deVetH, van derHeijdeD, van derLindenS (2001)Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 28:1056-1062
7. Van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124
8. Dagfinrud H, Mengshoel AM, Hagan KB, Loge JH, Kvien TK (2004) Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 63:1605-1610
9. Elkayam O, Litinsky I, Levartovsky D, Caspi D (2008) The changing face of spondyloarthropathies under TNF a blockade. Open Rheumatol J 2:53-57
10. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817-824
11. van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591
12. Paul S, Keat A (2005) Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. Rheumatology 44:17-23
13. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
14. Mackay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27:2866-2872
15. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
16. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994)Anew approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
17. Harris WH (1969) Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An endresult study using a new method of result evaluation. J Bone Joint Surg Am 51(4):737-755
18. Calin A, Elswood J (1988) The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis-one disease process or several? Br J Rheumatol 27:393-395
19. Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC Jr (2008) Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 67:233-237
20. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J (2006) Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-α antibody infliximab. Rheumatology 45:129-138
21. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P, BSR Standards, Guidelines and Audit Working group (2005) BSR guidelines for prescribing TNF-αlpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 44:939-947
22. Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966-970
23. Russell AS, Orozco JH, Maksymowych WP (2002) The dosage of infliximab in the treatment of ankylosing spondylitis: dollars and sense. Clin Exp Rheumatol 20(Suppl 28):s135-s136
24. Sidirooulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K, Boumpas DT (2005) Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23:513-516
25. Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DG (2006) Low-dose infliximab treatment for ankylosing spondylitis clinically and cost effective. Rheumatology (Oxford) 45:1566-1569
26. Keeling S, Oswald A, Russell AS, Maksymowych WP (2006) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/Kg) infliximab in ankylosing spondylitis: 4-year follow up. J Rheumatol 33:558-561
27. Lee SH, Lee YA, Hong SJ, Yang HI (2008) Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 27:179-181
28. Gadsby K, Deighton C (2007) Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. Rheumatology (Oxford) 46:439-441